Paul Audhya Divests 1,163 Shares of KalVista Pharmaceuticals Stock

Insider transactions at public companies often draw attention, particularly when significant sales occur. On February 18, 2024, Paul Audhya, an insider at KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), sold 1,163 shares of the company’s stock. The shares were sold at an average price of $15.00, resulting in a total transaction value of approximately $17,445. After this sale, Audhya retained ownership of 133,087 shares, amounting to a value of roughly $1,996,305. This sale marks a 0.87% decrease in his overall ownership stake in KalVista.

The transaction was reported to the Securities and Exchange Commission, as required for insider trades, ensuring transparency in the firm’s operations. KalVista Pharmaceuticals is a clinical-stage biotechnology company focused on developing small-molecule protease inhibitors targeting rare and specialty diseases.

Current Stock Performance and Analyst Ratings

As of Friday, February 19, 2024, KalVista Pharmaceuticals stock opened at $15.83. The company’s stock has demonstrated some volatility, with a 50-day simple moving average of $15.50 and a 200-day simple moving average of $13.88. Currently, the firm holds a market capitalization of $800.14 million and has a price-to-earnings ratio of -4.01. The stock’s beta stands at -0.19, indicating low volatility compared to the broader market.

KalVista’s stock has seen a 1-year low of $9.23 and a 1-year high of $19.00. In light of these fluctuations, several financial analysts have updated their price targets for the stock. HC Wainwright recently increased their target price from $27.00 to $37.00 and maintained a “buy” rating. Similarly, Needham & Company LLC raised their price objective from $28.00 to $32.00, also assigning a “buy” rating.

Despite these positive outlooks, Weiss Ratings issued a “sell (d-)” rating in a recent note. Overall, seven analysts have rated the stock a “buy,” while one has given it a “sell” rating. According to data from MarketBeat.com, the stock currently holds an average rating of “Moderate Buy” with a consensus target price of $29.40.

Recent Hedge Fund Activity

Hedge funds have shown increased interest in KalVista Pharmaceuticals recently. Emerald Advisers LLC expanded its stake by 30.2% during the third quarter, now owning 1,351,254 shares, valued at about $16,458,000. Emerald Mutual Fund Advisers Trust also increased its stake by 26.4% in the second quarter, bringing their total to 768,972 shares worth approximately $8,693,000.

Other notable changes include Stonepine Capital Management LLC, which grew its holdings by 364.0%, now owning 100,000 shares valued at about $1,130,000. F m Investments LLC and Panagora Asset Management Inc. also significantly increased their stakes, reflecting growing institutional confidence in KalVista’s prospects.

KalVista Pharmaceuticals continues to focus on innovative treatments, specifically targeting conditions associated with vascular leak, edema, and inflammation. The company’s lead programs include an oral plasma kallikrein inhibitor currently in trials for the acute treatment of hereditary angioedema attacks, as well as an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

With ongoing developments and changing market dynamics, KalVista Pharmaceuticals remains a company to watch in the biotechnology sector.